Please read the article authored by ITI titled, “The Use and Misuse of Cancer Life Expectancy Statistics” which explores how GBM patients adjust and deal with dire life expectancy statistics.

Senator McCain fought glioblastoma bravely. Our team, and scientists around the world, remain committed to researching treatment options.  Read Dr. Mitchell's article on the progress being made in the treatment

In Vivo feature titled, Cancer Vaccines: Is There A Future Beyond Trial And Error? While it has been a challenging R&D field, Looney notes that several key advances may soon

May is Brain Tumor Awareness Month. In the United States, an estimated 700,000 people are living with a primary brain tumor and 79,000 more will be diagnosed this year. Gliomas

Scientific American’s Custom Media division hosted a unique salon-style event in collaboration with Immunomic Therapeutics on Monday, February 12th in the heart of Manhattan’s Times Square. The forum, Hot Topics in Biotech:

Read how Astellas is working to address a high unmet medical need with first-of-its-kind allergy vaccine development through an innovative partnership. The following article was authored by Astellas and published on

Scientific American custom media and Immunomic Therapeutics released an article titled, “The Fight Against Cancer is Increasingly Personal,” by reclassifying tumors, scientists are finding a path to genuine cancer cures.

Sia Anagnostou, Senior Director at Immunomic Therapeutics authored this article, "Md. is developing the next generation of life-saving vaccines" in the Baltimore Sun. http://www.baltimoresun.com/news/opinion/oped/bs-ed-op-1020-vaccines-md-20171018-story.html  

A closer look at the social, cultural and political issues influencing immunization This article was produced for Immunomic Therapeutics by Scientific American Custom Media, a division separate from the magazine’s board of editors.

http://www.drug-dev.com/Main/Back-Issues/DNA-VACCINE-TECHNOLOGY-A-Vaccine-Breakthrough-That-981.aspx INTRODUCTION What if there was the potential for a better and safer treatment for allergies, a less-toxic cancer therapy, or a breakthrough treatment to improve the health of a

https://www.genengnews.com/gen-news-highlights/immunomic-negotiates-license-to-trianni-mouse-for-human-antibody-discovery/81254369 Immunomic Negotiates License to Trianni Mouse for Human Antibody Discovery Trianni granted Immunomic Therapeutics a license to its Trianni Mouse™ platform for generating fully human antibodies. Immunomic said it

https://immuno-oncologynews.com/2017/05/18/cancer-vaccine-based-on-immunotherapy-combo-by-immunomic-therapeutics-enters-trial-in-brain-cancer/ BY PATRICIA INACIO, PHD Immunomic Therapeutics has entered an exclusive licensing agreement with Annias Immunotherapeutics for the rights to use Annia’s intellectual property regarding an immunotherapy based on antigens